Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.
about
Interventional Nanotheranostics of Pancreatic Ductal AdenocarcinomaRecent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapyTargeted therapy using nanotechnology: focus on cancerThe potential of polymeric micelles in the context of glioblastoma therapy.Targeted delivery of doxorubicin-loaded poly (ε-caprolactone)-b-poly (N-vinylpyrrolidone) micelles enhances antitumor effect in lymphomaClinical Translation of Nanomedicine.Multifunctional polymeric micelles for delivery of drugs and siRNA.Beta-cyclodextrin-centered star-shaped amphiphilic polymers for doxorubicin delivery.Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective.Controlled synthesis of camptothecin-polylactide conjugates and nanoconjugatesPolymeric micelle nanoparticles for photodynamic treatment of head and neck cancer cells.Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.Enabling individualized therapy through nanotechnologyNovel nanomaterials for clinical neuroscience.Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer.Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivoMulti-stage delivery nano-particle systems for therapeutic applicationsPolylactide-cyclosporin A nanoparticles for targeted immunosuppression.Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumorsPeripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors aCore-Crosslinked Polymeric Micelles: Principles, Preparation, Biomedical Applications and Clinical TranslationPolymer genomics: an insight into pharmacology and toxicology of nanomedicinesPerspectives on clinical translation of smart nanotherapeutics.Drug delivery strategies for cathepsin inhibitors in joint diseases.Polymeric micelles for drug delivery.Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation.Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.Block copolymer micelles as delivery vehicles of hydrophobic drugs: micelle-cell interactions.Controlled Multi-functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells.Building Nanostructures with Drugs.Pluronic mixed micelles overcoming methotrexate multidrug resistance: in vitro and in vivo evaluation.Targeted polymeric therapeutic nanoparticles: design, development and clinical translationPolymeric micelles for drug targeting.Past and future evolution in colloidal drug delivery systems.Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide).Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs.Polyamide Nanogels from Generally Recognized as Safe Components and Their Toxicity in Mouse Preimplantation Embryos.Factors affecting the clearance and biodistribution of polymeric nanoparticles.
P2860
Q26744830-B754EB78-0D9D-4DFF-B4E3-893FDAF4F057Q26745710-E6F98E9A-6C85-49FD-B3EA-59CAEA8D66D1Q27023361-4AA9AFAF-9614-4619-A8DE-613CA6BD7F3CQ27693205-0711BE30-F3C6-43DC-9840-61D0BB1F89C3Q28537594-0B999BB3-0B09-415A-850F-C6D59FE7F575Q30355939-A40B2037-69D6-4921-A2F5-6C7E21E64CADQ30438973-924CDD13-63FB-42D3-B10D-7F31B61062C2Q33530676-016A66B3-9B3E-4263-84CE-ACDE87911BA6Q33553453-BD1613BA-E5F6-4982-9BF0-0F6FD08EFD96Q33601744-0483988E-3F1A-4983-A771-0D872EE78C2AQ33629833-12A7956C-6D3B-4AE9-8FAF-459ECF545B81Q33726019-DD9F4483-FC4F-41C9-A23A-DBE4A38AEB27Q33902253-417CA65B-FDFC-4763-BCE3-09930FD65869Q33917755-E39E8019-043A-46B1-94CB-8EF7D60D08E4Q34009532-635CE03E-F472-4BD1-B32C-706585AA92B3Q34054263-E692FEC1-8987-4EFD-B92D-5A15527F3CD9Q34104079-1719BD28-8BDB-4D1E-BC26-645D1611D764Q34166491-EEE6C1BC-28E8-4C5F-A94B-AC2BFE67251BQ34378940-D696EABB-7EDF-403F-B7D4-C52697B6597AQ34647228-B1880B4F-EFCF-4E76-A3BE-A99DE8D00014Q35085896-2C06241A-AB49-473A-841F-BB9B9BFCEA57Q35438759-6CE469E3-876A-4BC8-B808-ACAA37E4A1C5Q35754353-6BCFAEAF-6704-4A3C-A33C-F2747305F8F0Q36028787-0AEB198D-D901-42D8-A925-147576F120D3Q36316921-5508EC4F-1C4A-4A9C-9DD0-536FB28252CEQ36349714-2DD9CF4A-704F-4D7E-A053-CD10C2870D5EQ36412928-5E80EC5E-99D5-4BF2-B32F-868E65D683E0Q36610814-526D7492-5C01-435E-A7BD-6D6222F0C740Q36615327-27585F5A-7298-4CCD-87FB-3BE848141201Q36648447-23C0DC49-66B7-49E1-B90E-4BC701741BD0Q36760447-097667D8-6E37-4C47-872C-F33A5D73E1DCQ36766960-31006038-9334-4574-8F35-3B80AB02535DQ36779964-9D5344A1-7366-43EF-8D04-EEC57266D62DQ36934007-266137C3-065B-4348-94C6-FA3644B0F096Q36985038-BC782CC2-A7D7-42A3-B411-DD5993D90CA3Q37039030-C30AA1D2-07A9-4CF0-986F-904C8E4AA3E5Q37056787-D85C1023-F315-444E-BF1D-ABB0424E9AADQ37141404-B628FEF9-E5EE-4AC5-8CA4-F89E1F7C70C0Q37145696-83F71383-FDB8-4EF4-B7EE-316E7CF4FF97Q37146591-5C332B96-3E38-4F25-85CC-BA87BB077EE2
P2860
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Phase I clinical trial and pha ...... elle-encapsulated doxorubicin.
@ast
Phase I clinical trial and pha ...... elle-encapsulated doxorubicin.
@en
type
label
Phase I clinical trial and pha ...... elle-encapsulated doxorubicin.
@ast
Phase I clinical trial and pha ...... elle-encapsulated doxorubicin.
@en
prefLabel
Phase I clinical trial and pha ...... elle-encapsulated doxorubicin.
@ast
Phase I clinical trial and pha ...... elle-encapsulated doxorubicin.
@en
P2093
P2860
P356
P1476
Phase I clinical trial and pha ...... elle-encapsulated doxorubicin.
@en
P2093
Hamaguchi T
Matsumura Y
Watanabe N
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602204
P407
P577
2004-11-01T00:00:00Z